Raltitrexed (Tomudex™) in combination with 5-fluorouracil for the treatment of patients with advanced colorectal cancer: preliminary results from phase I clinical trials

摘要: Abstract The potential of raltitrexed (Tomudex™) in combination with 5-fluorouracil (5-FU) as treatment for advanced colorectal cancer has been investigated two phase I clinical trials. In the first study, was combined bolus 5-FU; patients received a 15-min infusion followed 24 h later by 5-FU every 3 weeks. second administered weekly 24-h 5 weeks 6-week cycle and given prior to on days 8 29. recommended dose is likely be 1200 mg/m 2 dose-limiting toxicity (DLT) febrile neutropenia observed at 1350 mg/m , but escalation above used single-agent use (3.0 mg/m ) continues. raltitrexed/infusional also still continuing, only men no DLT men; female had myelosuppression diarrhoea 3.0 mg/m infusional 2400 mg/m . Raltitrexed significant effect pharmacokinetics irrespective regimen. Preliminary response data encouraging 53% receiving showing partial response. addition, disease stabilisation who previously failed therapy. Recruitment recently commenced studies which oral derivatives 5-FU. conclusion, preliminary from these indicate that well tolerated activity. ©